Cargando…

Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations

Whole exome sequencing (WES) of matched tumor-normal pairs in rare tumors has the potential to identify genome-wide mutations and copy number alterations (CNAs). We evaluated 27 rare cancer patients with tumor-normal matching by WES and tumor-only next generation sequencing (NGS) as a comparator. Ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Sprissler, Ryan, Perkins, Bryce, Johnstone, Laurel, Babiker, Hani M., Chalasani, Pavani, Lau, Branden, Hammer, Michael, Mahadevan, Daruka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352311/
https://www.ncbi.nlm.nih.gov/pubmed/32570879
http://dx.doi.org/10.3390/cancers12061618
_version_ 1783557608149352448
author Sprissler, Ryan
Perkins, Bryce
Johnstone, Laurel
Babiker, Hani M.
Chalasani, Pavani
Lau, Branden
Hammer, Michael
Mahadevan, Daruka
author_facet Sprissler, Ryan
Perkins, Bryce
Johnstone, Laurel
Babiker, Hani M.
Chalasani, Pavani
Lau, Branden
Hammer, Michael
Mahadevan, Daruka
author_sort Sprissler, Ryan
collection PubMed
description Whole exome sequencing (WES) of matched tumor-normal pairs in rare tumors has the potential to identify genome-wide mutations and copy number alterations (CNAs). We evaluated 27 rare cancer patients with tumor-normal matching by WES and tumor-only next generation sequencing (NGS) as a comparator. Our goal was to: 1) identify known and novel variants and CNAs in rare cancers with comparison to common cancers; 2) examine differences between germline and somatic variants and how that functionally impacts rare tumors; 3) detect and characterize alleles in biologically relevant genes-pathways that may be of clinical importance but not represented in classical cancer genes. We identified 3343 germline single nucleotide variants (SNVs) and small indel variants—1670 in oncogenes and 1673 in tumor suppressor genes—generating an average of 124 germline variants/case. The number of somatic SNVs and small indels detected in all cases was 523:306 in oncogenes and 217 in tumor suppressor genes. Of the germline variants, six were identified to be pathogenic or likely pathogenic. In the 27 analyzed rare cancer cases, CNAs are variable depending on tumor type, germline pathogenic variants are more common. Cell fate pathway mutations (e.g., Hippo, Notch, Wnt) dominate pathogenesis and double hit (mutation + CNV) represent ~18% cases.
format Online
Article
Text
id pubmed-7352311
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73523112020-07-21 Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations Sprissler, Ryan Perkins, Bryce Johnstone, Laurel Babiker, Hani M. Chalasani, Pavani Lau, Branden Hammer, Michael Mahadevan, Daruka Cancers (Basel) Article Whole exome sequencing (WES) of matched tumor-normal pairs in rare tumors has the potential to identify genome-wide mutations and copy number alterations (CNAs). We evaluated 27 rare cancer patients with tumor-normal matching by WES and tumor-only next generation sequencing (NGS) as a comparator. Our goal was to: 1) identify known and novel variants and CNAs in rare cancers with comparison to common cancers; 2) examine differences between germline and somatic variants and how that functionally impacts rare tumors; 3) detect and characterize alleles in biologically relevant genes-pathways that may be of clinical importance but not represented in classical cancer genes. We identified 3343 germline single nucleotide variants (SNVs) and small indel variants—1670 in oncogenes and 1673 in tumor suppressor genes—generating an average of 124 germline variants/case. The number of somatic SNVs and small indels detected in all cases was 523:306 in oncogenes and 217 in tumor suppressor genes. Of the germline variants, six were identified to be pathogenic or likely pathogenic. In the 27 analyzed rare cancer cases, CNAs are variable depending on tumor type, germline pathogenic variants are more common. Cell fate pathway mutations (e.g., Hippo, Notch, Wnt) dominate pathogenesis and double hit (mutation + CNV) represent ~18% cases. MDPI 2020-06-18 /pmc/articles/PMC7352311/ /pubmed/32570879 http://dx.doi.org/10.3390/cancers12061618 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sprissler, Ryan
Perkins, Bryce
Johnstone, Laurel
Babiker, Hani M.
Chalasani, Pavani
Lau, Branden
Hammer, Michael
Mahadevan, Daruka
Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations
title Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations
title_full Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations
title_fullStr Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations
title_full_unstemmed Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations
title_short Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations
title_sort rare tumor-normal matched whole exome sequencing identifies novel genomic pathogenic germline and somatic aberrations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352311/
https://www.ncbi.nlm.nih.gov/pubmed/32570879
http://dx.doi.org/10.3390/cancers12061618
work_keys_str_mv AT sprisslerryan raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations
AT perkinsbryce raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations
AT johnstonelaurel raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations
AT babikerhanim raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations
AT chalasanipavani raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations
AT laubranden raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations
AT hammermichael raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations
AT mahadevandaruka raretumornormalmatchedwholeexomesequencingidentifiesnovelgenomicpathogenicgermlineandsomaticaberrations